Article Information
vol. 30 no. 159
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 4, 2020
- Accepted November 13, 2020
- Published online February 16, 2021.
Copyright & Usage
Copyright ©ERS 2021 This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Bernadette J. Prentice1,2⇑,
- Adam Jaffe1,2,
- Shihab Hameed2,3,4,
- Charles F. Verge2,4,
- Shafagh Waters2,5 and
- John Widger1,2
- 1Dept of Respiratory Medicine, Sydney Children's Hospital, Randwick, Australia
- 2School of Women's and Children's Health, University of New South Wales, Sydney, Randwick, Australia
- 3Faculty of Medicine, University of Sydney, Sydney, Australia
- 4Dept of Endocrinology, Sydney Children's Hospital, Randwick, Australia
- 5MiCF Research Centre, Sydney, Australia
- Correspondence: Bernadette Prentice, Dept of Respiratory Medicine, Sydney Children's Hospital, High St, Randwick, NSW 2031, Australia. E-mail: Bernadette.prentice{at}health.nsw.gov.au
Article usage
Altmetrics
Vol 30 Issue 159
Table of Contents
Cystic fibrosis-related diabetes and lung disease: an update
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Pathophysiology of CFRD
- Clinical implications of CFRD
- Diabetes and nutrition
- Infection and hyperglycaemia
- Hyperglycaemia and the pulmonary microbiome
- Tissue damage
- ASL acid–base balance
- Hyperglycaemia and the effect on the inflammatory response
- Immunomodulation
- Receptor for advanced glycation end products
- CFRD genetic modifiers and the relationship with lung disease
- Future research avenues
- Conclusion
- Footnotes
- References
- Figures & Data
- Info & Metrics